비교리스트

 카트 문의
시장보고서
상품코드
1364782

세계의 에피제네틱스 의약품 및 진단 기술 시장 예측(-2032년)

Epigenetics Drugs and Diagnostic Technologies Market Research Report Forecast to 2032
발행일: | 리서치사: Market Research Future | 페이지 정보: 영문 128 Pages | 배송안내 : 문의

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 에피제네틱스 의약품 및 진단 기술 시장 규모는 조사 기간 동안 21.90%의 CAGR로 크게 성장할 것으로 예상됩니다.

지역별 인사이트

북미 시장은 진행성 질환의 발생 건수 증가와 Illumina, Inc. (미국), Gilead Sciences, Inc. (미국), Celleron Therapeutics (미국), LISEN lmprinting Diagnostics (미국), Salarius Drugs, Inc.(미국) 등 역동적인 주요 기업의 존재로 인해 2022년 가장 큰 시장 점유율을 차지했습니다.

유럽 시장은 유전성 질환의 우위성과 유전성 질환을 검출하는 에피제네틱스 검사의 보급으로 인해 시장 점유율 2위를 차지하고 있습니다.

아시아태평양 시장은 신경 질환의 발생 증가와 의약품 개발을 위한 조직적인 활동의 확대로 인해 건전한 시장 성장을 기록할 것으로 예상됩니다. 중국, 인도, 남아시아, 서태평양 인근 국가를 포함한 개발도상국에서는 노인 인구의 급속한 증가로 인해 알츠하이머병 발병률이 높아지고 있습니다.

이 보고서는 세계 에피제네틱스 의약품 및 진단 기술 시장에 대해 조사 분석했으며, 시장 역학, 지역 및 부문 분석, 기업 개요 등을 제공합니다.

목차

제1장 주요 요약

제2장 시장 서론

제3장 조사 방법

제4장 시장 역학

  • 개요
  • 성장 촉진요인
  • 성장 억제요인
  • 기회

제5장 시장 요인 분석

  • 밸류체인 분석
  • Porter's Five Forces 분석
  • COVID-19의 영향 분석
    • 시장에 대한 영향 분석
    • 지역에 대한 영향
    • 기회와 위협 분석

제6장 세계의 에피제네틱스 의약품 및 진단 기술 시장 : 의약품 유형별

  • 개요
  • DNA 메틸트랜스퍼라제(DNMT) 억제제
    • 아자시티딘
    • 데시타빈
    • 기타
  • 히스톤 탈아세틸화효소(HDAC) 억제제
    • 보리노스타트
    • 로미뎁신
    • 기타
  • 히스톤 메틸트랜스퍼라제(HMT) 억제제
  • 기타

제7장 세계의 에피제네틱스 의약품 및 진단 기술 시장 : 진단 기술별

  • 개요
  • DNA 메틸화
  • 히스톤 변형 해석
  • 기타

제8장 세계의 에피제네틱스 의약품 및 진단 기술 시장 : 용도별

  • 개요
  • 종양
  • 신경
  • 자가면역질환
  • 기타

제9장 세계의 에피제네틱스 의약품 및 진단 기술 시장 : 최종사용자별

  • 개요
  • 병원·진료소
  • 진단 연구소
  • 기타

제10장 세계의 에피제네틱스 의약품 및 진단 기술 시장 : 지역별

  • 개요
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 프랑스
    • 영국
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 호주
    • 기타 아시아태평양
  • 기타 지역
    • 중동
    • 아프리카
    • 라틴아메리카

제11장 기업 상황

  • 개요
  • 경쟁 분석
  • 시장 점유율 분석
  • 세계의 에피제네틱스 의약품 및 진단 기술 시장의 주요 성장 전략
  • 경쟁 벤치마킹
  • 세계의 에피제네틱스 의약품 및 진단 기술 시장의 개발수 주요 기업
  • 주요 발전과 성장 전략
  • 주요 기업 재무 매트릭스

제12장 기업 개요

  • HOLOGIC, INC.
  • GILEAD SCIENCES, INC.
  • CELLERON THERAPEUTICS
  • ILLUMINA, INC.
  • ASTRAZENECA PLC
  • LISEN LMPRINTING DIAGNOSTICS
  • SALARIUS PHARMACEUTICALS, INC.
  • JUBILANT THERAPEUTICS
  • ORYZON GENOMICS
  • EPIAXIS THERAPEUTICS

제13장 부록

ksm 23.10.26

Market Overview

The Epigenetics Drugs and Diagnostic Technologies Market is anticipated to register a substantial CAGR of 21.90% during the review period.

The development of the market is driven by elements like the rising pervasiveness of persistent diseases like Focal Sensory system (CNS) diseases and oncology and the rising number of product dispatches and pipeline products.

The rising incidences of ongoing diseases of the focal sensory system across the globe are expanding the demand for epigenetic drugs and diagnostic technologies. Epigenetics significantly treat focal sensory system diseases, including Alzheimer's, Huntington's disease, schizophrenia, chemical imbalance, and bipolar disorder. Moreover, these drugs have low poisonousness and can be given in mix with different kinds of drugs for better treatment.

Additionally, epigenetics has shown extraordinary outcomes in treating malignant growth, and these drugs could switch off Deoxyribonucleic Acid (DNA). According to GLOBOCAN 2020, bosom disease accounted for the biggest offer, followed by lung, colorectum, prostate, stomach, and different malignant growths.

Market Segmentation

The market segments of epigenetics drugs and diagnostic technologies, based on drug type, into DNA methyltransferases (DNMTs) inhibitors, histone deacetylases (HDACs) inhibitors, histone methyltransferase (HMT) inhibitors, and others including bromodomain inhibitors, protein methyltransferase inhibitors, and histone acetyltransferases (HAT) inhibitors. The DNA methyltransferases (DNMTs) inhibitors segment is further segmented into azacitidine, decitabine, and others including zebularine, hydralazine, and procaine, and histone deacetylases (HDACs) inhibitors are further segmented into vorinostat, romidepsin, and others including belinostat, panobinostat, and trichostatin A.

The diagnostic technologies segment is classified into DNA methylation and histone modification analysis and others, including non-coding RNA analysis and epigenomic profiling.

Based on application, the market is separated into oncology, neurology, autoimmune diseases, and others. Based on end users the market is segmented into hospitals & and clinics, diagnostic centers, and others, including academic and research institutes and ambulatory surgical centers.

Regional Insights

North America epigenetics drugs and diagnostic technologies market held the biggest market share in 2022, due to the rising incidences of ongoing diseases and the presence of major and dynamic players including Illumina, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), LISEN lmprinting Diagnostics (US), and Salarius Drugs, Inc. (US).

Europe's epigenetics drugs and diagnostic technologies market accounted for the second-biggest market share due to the rising predominance of hereditary disorders and the send-off of epigenetic tests to detect hereditary disorders.

The Asia-Pacific epigenetics drugs and diagnostic technologies market is anticipated to register a healthy market growth owing to the developing incidence of neurological diseases and expanding coordinated efforts for the development of the drugs. According to the Alzheimer's Disease Global revealed in 2020, there are higher possibilities of Alzheimer's in developing nations including China, India, South Asia, and Western Pacific neighbors due to the quick development of the geriatric populace.

Major Players

Key Companies in the market of Epigenetics Drugs and Diagnostic Technologies are Hologic, Inc. (US), Gilead Sciences, Inc. (US), Celleron Therapeutics (US), Illumina, Inc. (US), AstraZeneca PLC (UK), LISEN lmprinting Diagnostics (US), Salarius Pharmaceuticals, Inc. (US), Jubilant Therapeutics (US), Oryzon Genomics (Spain), and Epiaxis Therapeutics (Australia).

TABLE OF CONTENTS

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

  • 2.1. DEFINITION
  • 2.2. SCOPE OF THE STUDY
    • 2.2.1. RESEARCH OBJECTIVE
    • 2.2.2. ASSUMPTIONS
    • 2.2.3. LIMITATIONS

3. RESEARCH METHODOLOGY

  • 3.1. OVERVIEW
  • 3.2. DATA MINING
  • 3.3. SECONDARY RESEARCH
  • 3.4. PRIMARY RESEARCH
    • 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
    • 3.4.2. BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5. FORECASTING TECHNIQUE
  • 3.6. MARKET SIZE ESTIMATION
    • 3.6.1. BOTTOM-UP APPROACH
    • 3.6.2. TOP-DOWN APPROACH
  • 3.7. DATA TRIANGULATION
  • 3.8. VALIDATION

4. MARKET DYNAMICS

  • 4.1. OVERVIEW
  • 4.2. DRIVERS
  • 4.3. RESTRAINTS
  • 4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

  • 5.1. VALUE CHAIN ANALYSIS
  • 5.2. PORTER'S FIVE FORCES ANALYSIS
    • 5.2.1. BARGAINING POWER OF SUPPLIERS
    • 5.2.2. BARGAINING POWER OF BUYERS
    • 5.2.3. THREAT OF NEW ENTRANTS
    • 5.2.4. THREAT OF SUBSTITUTES
    • 5.2.5. INTENSITY OF RIVALRY
  • 5.3. COVID-19 IMPACT ANALYSIS
    • 5.3.1. MARKET IMPACT ANALYSIS
    • 5.3.2. REGIONAL IMPACT
    • 5.3.3. OPPORTUNITY AND THREAT ANALYSIS

6. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DRUG TYPE

  • 6.1. OVERVIEW
  • 6.2. DNA METHYLTRANSFERASES (DNMTS) INHIBITORS
    • 6.2.1. AZACITIDINE
    • 6.2.2. DECITABINE
    • 6.2.3. OTHERS
  • 6.3. HISTONE DEACETYLASES (HDACS) INHIBITORS
    • 6.3.1. VORINOSTAT
    • 6.3.2. ROMIDEPSIN
    • 6.3.3. OTHERS
  • 6.4. HISTONE METHYLTRANSFERASE (HMT) INHIBITORS
  • 6.5. OTHERS

7. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY DIAGNOSTIC TECHNOLOGIES

  • 7.1. OVERVIEW
  • 7.2. DNA METHYLATION
  • 7.3. HISTONE MODIFICATION ANALYSIS
  • 7.4. OTHERS

8. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY APPLICATION

  • 8.1. OVERVIEW
  • 8.2. ONCOLOGY
  • 8.3. NEUROLOGY
  • 8.4. AUTOIMMUNE DISEASES
  • 8.5. OTHERS

9. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY END USER

  • 9.1. OVERVIEW
  • 9.2. HOSPITALS & CLINICS
  • 9.3. DIAGNOSTIC LABORATORIES
  • 9.4. OTHERS

10. GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET, BY REGION

  • 10.1. OVERVIEW
  • 10.1. NORTH AMERICA
    • 10.1.1. US
    • 10.1.2. CANADA
  • 10.2. EUROPE
    • 10.2.1. GERMANY
    • 10.2.2. FRANCE
    • 10.2.3. UK
    • 10.2.4. ITALY
    • 10.2.5. SPAIN
    • 10.2.6. REST OF EUROPE
  • 10.3. ASIA-PACIFIC
    • 10.3.1. CHINA
    • 10.3.2. INDIA
    • 10.3.3. JAPAN
    • 10.3.4. SOUTH KOREA
    • 10.3.5. AUSTRALIA
    • 10.3.6. REST OF ASIA-PACIFIC
  • 10.4. REST OF THE WORLD
    • 10.4.1. MIDDLE EAST
    • 10.4.2. AFRICA
    • 10.4.3. LATIN AMERICA

11. COMPANY LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. COMPETITIVE ANALYSIS
  • 11.3. MARKET SHARE ANALYSIS
  • 11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
  • 11.5. COMPETITIVE BENCHMARKING
  • 11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET
  • 11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
    • 11.7.1. NEW PRODUCT LAUNCH
    • 11.7.2. MERGER & ACQUISITIONS
    • 11.7.3. JOINT VENTURES
  • 11.8. MAJOR PLAYERS FINANCIAL MATRIX
    • 11.8.1. SALES & OPERATING INCOME, 2022
    • 11.8.2. MAJOR PLAYERS R&D EXPENDITURE. 2022

12. COMPANY PROFILES

  • 12.1. HOLOGIC, INC.
    • 12.1.1. COMPANY OVERVIEW
    • 12.1.2. FINANCIAL OVERVIEW
    • 12.1.3. PRODUCTS OFFERED
    • 12.1.4. KEY DEVELOPMENTS
    • 12.1.5. SWOT ANALYSIS
    • 12.1.6. KEY STRATEGIES
  • 12.2. GILEAD SCIENCES, INC.
    • 12.2.1. COMPANY OVERVIEW
    • 12.2.2. FINANCIAL OVERVIEW
    • 12.2.3. PRODUCTS OFFERED
    • 12.2.4. KEY DEVELOPMENTS
    • 12.2.5. SWOT ANALYSIS
    • 12.2.6. KEY STRATEGIES
  • 12.3. CELLERON THERAPEUTICS
    • 12.3.1. COMPANY OVERVIEW
    • 12.3.2. FINANCIAL OVERVIEW
    • 12.3.3. PRODUCTS OFFERED
    • 12.3.4. KEY DEVELOPMENTS
    • 12.3.5. SWOT ANALYSIS
    • 12.3.6. KEY STRATEGIES
  • 12.4. ILLUMINA, INC.
    • 12.4.1. COMPANY OVERVIEW
    • 12.4.2. FINANCIAL OVERVIEW
    • 12.4.3. PRODUCTS OFFERED
    • 12.4.4. KEY DEVELOPMENTS
    • 12.4.5. SWOT ANALYSIS
    • 12.4.6. KEY STRATEGIES
  • 12.5. ASTRAZENECA PLC
    • 12.5.1. COMPANY OVERVIEW
    • 12.5.2. FINANCIAL OVERVIEW
    • 12.5.3. PRODUCTS OFFERED
    • 12.5.4. KEY DEVELOPMENTS
    • 12.5.5. SWOT ANALYSIS
    • 12.5.6. KEY STRATEGIES
  • 12.6. LISEN LMPRINTING DIAGNOSTICS
    • 12.6.1. COMPANY OVERVIEW
    • 12.6.2. FINANCIAL OVERVIEW
    • 12.6.3. PRODUCTS OFFERED
    • 12.6.4. KEY DEVELOPMENTS
    • 12.6.5. SWOT ANALYSIS
    • 12.6.6. KEY STRATEGIES
  • 12.7. SALARIUS PHARMACEUTICALS, INC.
    • 12.7.1. COMPANY OVERVIEW
    • 12.7.2. FINANCIAL OVERVIEW
    • 12.7.3. PRODUCTS OFFERED
    • 12.7.4. KEY DEVELOPMENTS
    • 12.7.5. SWOT ANALYSIS
    • 12.7.6. KEY STRATEGIES
  • 12.8. JUBILANT THERAPEUTICS
    • 12.8.1. COMPANY OVERVIEW
    • 12.8.2. FINANCIAL OVERVIEW
    • 12.8.3. PRODUCTS OFFERED
    • 12.8.4. KEY DEVELOPMENTS
    • 12.8.5. SWOT ANALYSIS
    • 12.8.6. KEY STRATEGIES
  • 12.9. ORYZON GENOMICS
    • 12.9.1. COMPANY OVERVIEW
    • 12.9.2. FINANCIAL OVERVIEW
    • 12.9.3. PRODUCTS OFFERED
    • 12.9.4. KEY DEVELOPMENTS
    • 12.9.5. SWOT ANALYSIS
    • 12.9.6. KEY STRATEGIES
  • 12.10. EPIAXIS THERAPEUTICS
    • 12.10.1. COMPANY OVERVIEW
    • 12.10.2. FINANCIAL OVERVIEW
    • 12.10.3. PRODUCTS OFFERED
    • 12.10.4. KEY DEVELOPMENTS
    • 12.10.5. SWOT ANALYSIS
    • 12.10.6. KEY STRATEGIES

13. APPENDIX

  • 13.1. REFERENCES
  • 13.2. RELATED REPORTS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제